Revolution Medicines Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $32.715
- Today's High:
- $33.45
- Open Price:
- $32.85
- 52W Low:
- $17.03
- 52W High:
- $35.5
- Prev. Close:
- $32.87
- Volume:
- 665720
Company Statistics
- Market Cap.:
- $3.83 billion
- Book Value:
- 8.529
- Revenue TTM:
- $29.52 million
- Operating Margin TTM:
- -1091.3%
- Gross Profit TTM:
- $-217693000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.6%
- Return on Equity TTM:
- -41.44%
Company Profile
Revolution Medicines Inc had its IPO on 2020-02-13 under the ticker symbol RVMD.
The company operates in the Healthcare sector and Biotechnology industry. Revolution Medicines Inc has a staff strength of 292 employees.
Stock update
Shares of Revolution Medicines Inc opened at $32.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $32.72 - $33.45, and closed at $32.89.
This is a +0.06% increase from the previous day's closing price.
A total volume of 665,720 shares were traded at the close of the day’s session.
In the last one week, shares of Revolution Medicines Inc have slipped by -6.16%.
Revolution Medicines Inc's Key Ratios
Revolution Medicines Inc has a market cap of $3.83 billion, indicating a price to book ratio of 3.1624 and a price to sales ratio of 72.2422.
In the last 12-months Revolution Medicines Inc’s revenue was $29.52 million with a gross profit of $-217693000 and an EBITDA of $-317656992. The EBITDA ratio measures Revolution Medicines Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Revolution Medicines Inc’s operating margin was -1091.3% while its return on assets stood at -23.6% with a return of equity of -41.44%.
In Q2, Revolution Medicines Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 58.1%.
Revolution Medicines Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.29 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Revolution Medicines Inc’s profitability.
Revolution Medicines Inc stock is trading at a EV to sales ratio of 53.0376 and a EV to EBITDA ratio of -6.6305. Its price to sales ratio in the trailing 12-months stood at 72.2422.
Revolution Medicines Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.07 billion
- Total Liabilities
- $78.06 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.12 million
- Dividend Payout Ratio
- 0%
Revolution Medicines Inc ended 2024 with $1.07 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.07 billion while shareholder equity stood at $930.84 million.
Revolution Medicines Inc ended 2024 with $0 in deferred long-term liabilities, $78.06 million in other current liabilities, 11000.00 in common stock, $-867737000.00 in retained earnings and $14.61 million in goodwill. Its cash balance stood at $380.33 million and cash and short-term investments were $909.49 million. The company’s total short-term debt was $5,718,000 while long-term debt stood at $0.
Revolution Medicines Inc’s total current assets stands at $922.09 million while long-term investments were $0 and short-term investments were $529.16 million. Its net receivables were $2.51 million compared to accounts payable of $29.78 million and inventory worth $0.
In 2024, Revolution Medicines Inc's operating cash flow was $0 while its capital expenditure stood at $1.12 million.
Comparatively, Revolution Medicines Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $32.89
- 52-Week High
- $35.5
- 52-Week Low
- $17.03
- Analyst Target Price
- $34.33
Revolution Medicines Inc stock is currently trading at $32.89 per share. It touched a 52-week high of $35.5 and a 52-week low of $35.5. Analysts tracking the stock have a 12-month average target price of $34.33.
Its 50-day moving average was $29.52 and 200-day moving average was $25.66 The short ratio stood at 10 indicating a short percent outstanding of 0%.
Around 178.4% of the company’s stock are held by insiders while 10586% are held by institutions.
Frequently Asked Questions About Revolution Medicines Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.